{"url_path":"/sec/derm/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1867066/0001104659-26-060297-index.html","accession_number":"0001104659-26-060297","cik":"0001867066","ticker":"DERM","issuer_name":"Journey Medical Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1867066/0001104659-26-060297-index.html","primary_entity_key":"0001867066","primary_entity_name":"Journey Medical Corp"},"word_count":72,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\nRule 10b5-1 Trading Plans\n\nDuring the three months ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended) adopted, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933).\n\n​\n\n25\n\n[Table of Contents](#TOC)"}